ELAINE COOK: Open Payments
NPI 1174504047 · NOTTINGHAM, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,232 in 51 payments from 9 companies in 2025. Trend: 2023 $1,254 · 2024 $1,113 · 2025 $1,232
Food & beverage: $1,232
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 9 | $322 |
| ABBVIE INC. | 14 | $251 |
| Indivior Inc. | 11 | $219 |
| Axsome Therapeutics, Inc. | 2 | $120 |
| Lundbeck LLC | 5 | $96 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $68 |
| Alkermes, Inc. | 3 | $55 |
| Vanda Pharmaceuticals Inc. | 2 | $54 |
| Teva Pharmaceuticals USA, Inc. | 2 | $46 |
Products named: INGREZZA, VRAYLAR, SUBLOCADE, Auvelity, REXULTI, CAPLYTA, HETLIOZ, VIVITROL.
Industry payments across MD — which companies pay providers there.
